Le Lézard
Classified in: Covid-19 virus
Subjects: Contract/Agreement, Product/Service

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") and Senores Pharmaceuticals, Inc. today announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg, a therapeutic generic equivalent of the reference listed drug Toradol Tablets, 10 mg in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).

Ketorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug ("NSAID") indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following intravenous or intramuscular dosing of ketorolac tromethamine, if necessary.

"We are pleased to partner with Dr. Reddy's Laboratories for the commercial launch of Ketorolac Tromethamine Tablets in the U.S. market," states Dhananjay Barot, Director, Senores Pharmaceuticals, Inc.

"Our constant dedication has contributed to expanding our product portfolio, and today we are a significant and reliable supplier of this product," states Swapnil Shah, Managing Director, Senores Group.

"We are excited about this launch, and pleased to partner with Senores to create affordable access to this product and expand our portfolio in the U.S. market," says Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories.

The Toradol Tablets, 10 mg brand and generic had U.S. sales of approximately $16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA*.

Dr. Reddy's Ketorolac Tromethamine Tablets USP, 10 mg, are available in bottle count sizes of 100.

Please click here to see the full prescribing information and approved indication, along with boxed warning for Dr. Reddy's Ketorolac Tromethamine Tablets USP, 10 mg.




Ketorolac tromethamine tablets, a nonsteroidal anti-inflammatory drug (NSAID), are indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine should not exceed 5 days.


Ketorolac tromethamine tablets are not indicated for use in pediatric patients and they are NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine tablets beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events.




  • Ketorolac tromethamine, including ketorolac tromethamine tablets can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).




  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS and PRECAUTIONS).
  • Ketorolac tromethamine tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS).




  • Ketorolac tromethamine is CONTRAINDICATED in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion (see WARNINGS).




  • Ketorolac tromethamine inhibits platelet function and is, therefore, CONTRAINDICATED in patients with suspected or confirmed cerebrovascular bleeding, patients with hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see WARNINGS and PRECAUTIONS).


Ketorolac tromethamine is CONTRAINDICATED as prophylactic analgesic before any major surgery.




  • The use of ketorolac tromethamine in labor and delivery is contraindicated because it may adversely affect fetal circulation and inhibituterine contractions.




  • Ketorolac tromethamine is CONTRAINDICATED in patients currently receiving aspirin or NSAIDs because of the cumulative risk of inducing serious NSAID-related side effects.




  • Dosage should be adjusted for patients 65 years or older, for patients under 50 kg (110 lbs) of body weight (see DOSAGE AND ADMINISTRATION) and for patients with moderately elevated serum creatinine (see WARNINGS).


Important Safety Information: Ketorolac Tromethamine Tablets, 10 mg

What Important Information Should I Know About Ketorolac Tromethamine Tablets, 10 mg?

Who Should Not Use Ketorolac Tromethamine Tablets, 10 mg?

What Should I Tell My Healthcare Ketorolac Tromethamine Tablets, 10 mg?

Before taking Ketorolac Tromethamine Tablets, tell your doctor if you:

What Are the Possible Side Effects of Ketorolac Tromethamine Tablets, 10 mg?

  • new or worse high blood pressure
  • heart failure
  • liver problems including liver failure
  • kidney problems including kidney failure
  • life-threatening skin reactions
  • low red blood cells (anemia)
  • life-threatening allergic reactions
  • shortness of breath or trouble breathing
  • slurred speech
  • chest pain
  • swelling of the face or throat
  • weakness in one part or side of your body
  • nausea
  • vomit blood
  • more tired or weaker than usual
  • blood in your bowel movement or it is black and sticky like tar
  • diarrhea
  • unusual weight gain
  • itching
  • skin rash or blisters with fever
  • your skin or eyes look yellow
  • swelling of the arms, legs, hands and feet
  • indigestion or stomach pain
  • flu-like symptoms

These are not all of the possible side effects of Ketorolac Tromethamine Tablets, 10 mg. Call your doctor for medical advice about side effects. For more information, ask your doctor or pharmacist. You are encouraged to report negative side effects of prescription drugs. To report suspected side effects, call Dr. Reddy's Laboratories Medical Information Call Center at 1-888-DRL-DRUG (1-888-375-3784) or via email to [email protected] or contact the US FDA at 1-800-FDA-1088 (1-800-332-1088) or online at http://www.fda.gov/safety/medwatch. Please refer to the Ketorolac Tromethamine Tablets, 10 mg Package Inserts for full Prescribing Information and Instructions for Use

Indication and Usage for Ketorolac Tromethamine Tablets, 10 mg

*IQVIA Retail and Non-Retail MAT March 2022.


About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include ? USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

About Senores Pharmaceuticals, Inc.

Senores Pharmaceuticals, based in Atlanta, Georgia is one of the fastest-growing pharmaceutical companies in the U.S. market. Currently, the company has more than 15 products commercially launched or filed with the USFDA. For more information, visit www.senorespharma.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.

These press releases may also interest you

at 12:05
Barrick Gold Corporation continues to invest in creating value for all stakeholders and in supporting the communities that host its mines, president and chief executive Mark Bristow said here today. Speaking to media at the company's...

at 03:45
Taiwan is set to welcome its first international sporting event following the outbreak of COVID-19. Over 200 delegates from 138 countries will be attending the 4th World Baseball Softball Confederation (WBSC) and Baseball Federation of Asia (BFA)...

1 jui 2022
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Novavax, Inc. ....

1 jui 2022
The "Smart Bottle Market by Application and Geography - Forecast and Analysis 2021-2025" report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for...

1 jui 2022
The Automotive HVAC Compressor Market is segmented by Geography (APAC, Europe, North America, South America, and MEA). 55% of the market's growth will originate from APAC during the forecast period. China, Japan, and India are the key markets...

1 jui 2022
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Yext, Inc. ("Yext" or "the Company") for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934...

News published on 24 may 2022 at 13:45 and distributed by: